SCHEMBL5834258

SCHEMBL5834258

CCCNc1ccc(N)cc1-c1nc2cc(-c3ccccc3)ccc2o1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPSE Q9Y251 12/20 0.59
MAPT P10636 7/20 0.48
SMN1; SMN2 Q16637 7/20 0.48
NPC1 O15118 7/20 0.48
RAB9A P51151 7/20 0.48
TP53 P04637 6/20 0.48
KDM4E B2RXH2 5/20 0.48
HSD17B10 Q99714 3/20 0.48
TSHR P16473 1/20 0.48
MEN1 O00255 4/20 0.47
ALDH1A1 P00352 4/20 0.47
KMT2A Q03164 4/20 0.47
HPGD P15428 3/20 0.47
ALOX15 P16050 2/20 0.46
GAA P10253 1/20 0.46
HTT P42858 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
GFER P55789 1/20 0.45
RXFP1 Q9HBX9 1/20 0.45
NFKB1 P19838 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5834754 0.94 HPSE (0.61) HPSEMAPTSMN1; SMN2NPC1RAB9A
SCHEMBL5834675 0.93 HPSE (0.57) HPSEMAPTSMN1; SMN2NPC1RAB9A
SCHEMBL5834444 0.92 HPSE (0.57) HPSEMAPTSMN1; SMN2NPC1RAB9A
SCHEMBL5834619 0.91 HPSE (0.58) HPSEMAPTSMN1; SMN2NPC1RAB9A
SCHEMBL5834161 0.91 HPSE (0.59) HPSEMAPTSMN1; SMN2NPC1RAB9A
SCHEMBL5834442 0.91 HPSE (0.59) HPSEMAPTSMN1; SMN2NPC1RAB9A
SCHEMBL5834486 0.90 HPSE (0.61) HPSEMAPTSMN1; SMN2NPC1RAB9A
SCHEMBL5834689 0.89 HPSE (0.61) HPSEMAPTSMN1; SMN2NPC1RAB9A
SCHEMBL5834390 0.88 HPSE (0.61) HPSEMAPTSMN1; SMN2NPC1RAB9A
SCHEMBL5834229 0.88 HPSE (0.60) HPSEMAPTSMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7138425-B2 Phthalimide carboxylic acid derivatives OXFORD GLYCOSCIENCE (UK) LTD. (GB) 2006-11-21 US disclosed
US-20050203153-A1 Phthalimide carboxylic acid derivatives OXFORD GLYCOSCIENCE (UK) LTD. (GB) 2005-09-15 US disclosed
EP-1483261-A1 PHTHALIMIDE CARBOXYLIC ACID DERIVATIVES Oxford GlycoSciences (UK) Ltd, Attn: Mary Gadsden (GB) 2004-12-08 EP disclosed
WO-2003074516-A1 PHTHALIMIDE CARBOXYLIC ACID DERIVATIVES OXFORD GLYCOSCIENCES (UK) LTD (GB) 2003-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203153-A1 Phthalimide carboxylic acid derivatives H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, IDH1 HPSE 2626/4885MAPT 1342/4885SMN1; SMN2 3147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.